Todos os estudos
AutorizadoExploratório terapêutico (Fase II)Intervencionista

Psilocybin in treatment-resistant depression

This research is exploring a new way to help people who have depression that hasn't improved with other common treatments. The study is investigating a substance called psilocybin. The main goal is to find out if taking psilocybin over four weeks can reduce the severity of depression symptoms, measured one week after the treatment period ends. This is a Phase II study, meaning it's still in the early stages of testing to see if the treatment works and is safe. It's an important step to understand if psilocybin could offer a new option for those struggling with long-term depression.

Em resumo

Status
Autorizado
Fase
Exploratório terapêutico (Fase II)
Patrocinador
LKH Graz II
Meta de inscrição
30
Iniciar
30 Jan 2025

Sobre o que é este estudo?

This study is about a type of depression called 'treatment-resistant depression'. This means that individuals have tried different treatments for their depression, like talking therapies or antidepressant medications, but their symptoms haven't really improved. It can be very frustrating and difficult to live with, so doctors and researchers are always looking for new ways to help.

The study is specifically looking at a substance called psilocybin. You might have heard of it because it's found in certain types of mushrooms. Researchers are carefully studying it in a medical setting to understand its effects on the brain and mood. They want to see if it could be a useful treatment for people whose depression has been difficult to manage with regular care.

The main aim is to see if, after a four-week period of taking psilocybin, participants feel less depressed one week later. This will be measured using a standard questionnaire that helps doctors understand how severe someone's depression is. This is an early-stage study, so it's about exploring whether psilocybin has a positive effect and is generally safe, rather than a final stamp of approval for treatment.

Pontos principais

  • New study for depression that hasn't responded to other treatments.
  • Investigating a substance called psilocybin.
  • Aims to see if depression symptoms improve after four weeks of treatment.
  • Open to adults aged 18 and over, both men and women.
  • It's a Phase II study, meaning it's an early exploration of the treatment.

Quem pode ser elegível?

This study is looking for adults who are 18 years old or older. There is no upper age limit, meaning older adults can also take part.

Participants can be male or female. The most important thing is that they have 'treatment-resistant depression', which means their depression hasn't gotten better with standard treatments they've tried in the past.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have depression that hasn't improved with other treatments?
  3. Are you able to commit to a four-week treatment period and follow-up?
  4. Have you spoken to your doctor about your depression?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, you would receive the psilocybin treatment over a period of four weeks. During and after this treatment period, you would have appointments where doctors and nurses would check your health and how you're feeling. They will use questionnaires, like the Beck Depression Inventory II, to measure any changes in your depression symptoms. The study will look at your symptoms one week after the four-week treatment ends. The total length of your involvement, including follow-up, will be explained fully by the study team.

Riscos e benefícios potenciais

Potential benefits of taking part could include an improvement in your depression symptoms, especially if other treatments haven't worked for you. However, as with any medical study, there are always potential risks; these will be fully explained to you before you decide to take part. These risks could include side effects from the medication or the experience of participating. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Localizações (1)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Áustria

Perguntas frequentes

What is psilocybin?

Psilocybin is a natural substance found in certain mushrooms that is being studied for its potential medical uses, including for depression.

What does 'treatment-resistant depression' mean?

It means depression that hasn't improved even after trying different common treatments like talking therapies or antidepressant medications.

Will I know if I'm getting the psilocybin or a dummy treatment?

In many studies like this, participants don't know what they're receiving. The study team will explain how this works.

Quanto tempo o estudo durará para mim?

The main treatment period is four weeks, and outcomes are checked one week afterwards. The full duration of your participation will be explained by the research team.

Onde este estudo está ocorrendo?

The information above doesn't say. The study team will be able to tell you the locations.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.